Statins and intracerebral hemorrhage: A retrospective cohort study

Archives of Neurology

Volumn 69, Issue 1, 2012, Pages 39-45

  Hackam, Daniel G ^a   Austin, Peter C ^b   Huang, Anjie ^b   Juurlink, David N ^b   Mamdani, Muhammad M ^b   Paterson, J Michael ^b   Hachinski, Vladimir ^a   Li, Ping ^b   Kapral, Moira K ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ROSUVASTATIN; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; TICLOPIDINE; WARFARIN;

AGED; ARTICLE; BONE DENSITY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANADA; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EMERGENCY WARD; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; CANADA; CEREBRAL HEMORRHAGE; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MULTICENTER STUDIES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STROKE;

EID: 81355125260     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.228     Document Type: Article

References (33)

1. van Wijk I, Kappelle LJ, van Gijn J, et al; LiLAC Study Group. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet. 2005;365(9477):2098-2104. (Pubitemid 40826967)
2. Furie KL, Kasner SE, Adams RJ, et al American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2011;42(1):227-276.
3. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery [published online May 25, 2011]. Circulation. doi:10.1161/CIR.0b013e31820d8c98.
4. Amarenco P, Bogousslavsky J, Callahan A III, et al Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559. (Pubitemid 44202151)
5. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-767.
6. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-463.
7. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39(2):497-502. (Pubitemid 351619482)
8. Serebruany VL, Malinin AI, Hennekens CH. Statins increase risk of hemorrhagic stroke by inhibition of the PAR-1 receptor. Cerebrovasc Dis. 2007;24(5):477-479. (Pubitemid 350017616)
9. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851-1861.
10. Squizzato A, Galli M, Romualdi E, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J. 2010;31(10):1248-1256.
11. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24(5):806-815. (Pubitemid 38620856)
12. Rordorf G, McDonald C. Spontaneous intracerebral hemorrhage: pathogenesis, clinical features, and diagnosis. In: Kasner SE, Wilterdink JL, eds. UpToDate, Version 18.2. Waltham, MA: UpToDate Inc; 2010.
13. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166(3):348-354. (Pubitemid 47216808)
14. Juurlink D, Preyra C, Croxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto, ON: Institute for Clinical Evaluative Sciences; 2006.
15. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10(2):67-71. (Pubitemid 37028596)
16. Lindsay MP, Kapral MK, Fang J, Tu JV, Laupacis A. Validation of administrative databases using a registry data source: implications for research on quality of stroke care [abstract P202]. Stroke. 2005;36(2):477.
17. Tu JV, Gong Y. Trends in treatment and outcomes for acute stroke patients in Ontario, 1992-1998. Arch Intern Med. 2003;163(3):293-297. (Pubitemid 36183857)
18. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167-176.
19. Saposnik G, Kapral MK, Liu Y, et al Investigators of the Registry of the Canadian Stroke Network; Stroke Outcomes Research Canada (SORCan) Working Group. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation. 2011;123(7):739-749.
20. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. (Pubitemid 37323253)
21. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8, pt 2):757-763. (Pubitemid 27446562)
22. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228-1234. doi:10.1080/03610910902859574.
23. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
24. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10. Stroke. 2005;36(8):1776-1781. (Pubitemid 41098778)
25. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-779.
26. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. 46th ed. Ottawa, ON: Canadian Pharmacists Association; 2011.
27. Baigent C, Blackwell L, Emberson J, et al Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
28. Goldstein LB, Amarenco P, Szarek M, et al SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24, pt 2):2364-2370.
29. Amarenco P, Bogousslavsky J, Callahan AS, et al SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis. 2003;16(4):389-395.
30. Westover MB, Bianchi MT, Eckman MH, Greenberg SM. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol. 2011;68(5):573-579.
31. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology. 2001; 56(6):773-777. (Pubitemid 32240098)
32. O'Donnell MJ, Xavier D, Liu L, et al INTERSTROKE Investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-123.
33. Ovbiagele B, Schwamm LH, Smith EE, et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke. 2010;41 (7):1508-1513.